{"id":"genvoya-crushed-dose","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Elevated creatinine"},{"rate":null,"effect":"Rash"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Genvoya contains elvitegravir (integrase inhibitor), cobicistat (CYP3A4 inhibitor/booster), emtricitabine (nucleoside reverse transcriptase inhibitor), and tenofovir alafenamide (nucleotide reverse transcriptase inhibitor). The combination targets multiple steps of HIV replication: integrase catalyzes viral DNA integration into the host genome, while reverse transcriptase inhibitors block conversion of viral RNA to DNA. Cobicistat enhances elvitegravir bioavailability.","oneSentence":"Genvoya is a fixed-dose combination antiretroviral that inhibits HIV reverse transcriptase and integrase to suppress viral replication.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:47:12.833Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-naïve and treatment-experienced adults"},{"name":"HIV-1 infection in adolescents and children (weight-based dosing)"}]},"trialDetails":[{"nctId":"NCT03717129","phase":"PHASE4","title":"Analysis of Crushed and Whole Tablet Genvoya","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2019-04-15","conditions":"Healthy Volunteers","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["elvitegravir/cobicistat/emtricitabine/ tenofovir alafenamide"],"phase":"marketed","status":"active","brandName":"Genvoya Crushed Dose","genericName":"Genvoya Crushed Dose","companyName":"Johns Hopkins University","companyId":"johns-hopkins-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Genvoya is a fixed-dose combination antiretroviral that inhibits HIV reverse transcriptase and integrase to suppress viral replication. Used for HIV-1 infection in treatment-naïve and treatment-experienced adults, HIV-1 infection in adolescents and children (weight-based dosing).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}